RS50853B - Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji - Google Patents

Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji

Info

Publication number
RS50853B
RS50853B RSP-2009/0089A RSP20090089A RS50853B RS 50853 B RS50853 B RS 50853B RS P20090089 A RSP20090089 A RS P20090089A RS 50853 B RS50853 B RS 50853B
Authority
RS
Serbia
Prior art keywords
alkyl
group
cycloalkyl
aryl
fluoroalkyl
Prior art date
Application number
RSP-2009/0089A
Other languages
English (en)
Inventor
Laurent Dubois
Yannick Evanno
Luc Even
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of RS50853B publication Critical patent/RS50853B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Jedinjenje koje Odgovara formuli (I)u kojojX1, X2, X3, X4, Z1, Z2, Z3, Z4 i Z5 predstavljaju, nezavisno jedan od drugog, jedan atom vodonika ili halogeni atom ili grupu C1-C6-alkil, C3-C7-cikloalkil, C1-C6-fluoroalkil, C1-C6-alkoksi, C1-C6-fluoroalkoksi, cijano, C(O)NR1R2, nitro, NR1R2,C1-C6-tioalkil, -S(O)-C1-C6-alkil, -S(O)2-C1-C6-alkil, SO2NR1R2, NR3COR4, NR3SO2R5 ili aril;X5 predstavlja atom vodonika ili halogena ili grupu C1-C6-alkil, C1-C6-fluoroalkil; R predstavlja grupu 4-, 5-, 6- ili 7-indolil,R je eventualno supstituisan u poziciji 1, 2 i/ili 3 sa jednom ili više grupa izabranih između grupa C1-C6-alkil i C1-C6-fluoroalkil;R je eventualno supstituisan u poziciji 4, 5, 6 i/ili 7 sa jednom ili više grupa izabranih među atomima halogena, grupama C1-C6-alkil, C1-C6-fluoroalkil, C1-C6-alkoksi, C1-C6-fluoroalkoksi ;Y predstavlja atom vodonika ili grupu C1-C6-alkil;n je jednako 0, 1, 2 ili 3 ;R1 i R2, predstavljaju, nezavisno jedan od drugoga, jedan vodonikov atom ili grupu C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkil, ili aril ; ili R1 i R2 čine zajedno, sa atomom azota koji ih nosi, azetidin, pirolidin, piperidin, azepin, morfolin, tiomorfolin, piperazin, homopiperazin grupu, ova grupa je eventualno supstituisana sa jednom grupom C1-C6-alkil, C3-C7-cikloalkil, C3-C7-cikloalkil-C1-C3-alkil ili aril;R3 i R4, predstavljaju, nezavisno jedan od drugoga, jedan vodonikov atom ili grupu C1-C6-alkil ili aril;R5 predstavlja grupu C1-C6-alkil ili aril;u obliku baze ili adicione soli kiseline, kao i u obliku hidrata ili solvata.Prijava sadrži još 17 patentnih zahteva.
RSP-2009/0089A 2004-08-05 2005-08-02 Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji RS50853B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0408652A FR2874015B1 (fr) 2004-08-05 2004-08-05 Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
PCT/FR2005/002014 WO2006024776A1 (fr) 2004-08-05 2005-08-02 Derives de n-(1 h-indolyl)-i h-ind0le-2-carb0xamides, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
RS50853B true RS50853B (sr) 2010-08-31

Family

ID=34950701

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2009/0089A RS50853B (sr) 2004-08-05 2005-08-02 Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji

Country Status (37)

Country Link
US (3) US7384969B2 (sr)
EP (1) EP1776340B1 (sr)
JP (1) JP5100381B2 (sr)
KR (1) KR101215162B1 (sr)
CN (1) CN101010297B (sr)
AR (1) AR050283A1 (sr)
AT (1) ATE416160T1 (sr)
AU (1) AU2005279085B2 (sr)
BR (1) BRPI0513087A (sr)
CA (1) CA2576727C (sr)
CR (1) CR8889A (sr)
CY (1) CY1108816T1 (sr)
DE (1) DE602005011450D1 (sr)
DK (1) DK1776340T3 (sr)
EA (1) EA011714B1 (sr)
EC (1) ECSP077215A (sr)
ES (1) ES2318542T3 (sr)
FR (1) FR2874015B1 (sr)
HR (1) HRP20090101T3 (sr)
IL (1) IL180911A (sr)
MA (1) MA28845B1 (sr)
ME (1) ME01663B (sr)
MX (1) MX2007001436A (sr)
MY (1) MY139286A (sr)
NO (1) NO340060B1 (sr)
NZ (1) NZ552924A (sr)
PE (1) PE20060557A1 (sr)
PL (1) PL1776340T3 (sr)
PT (1) PT1776340E (sr)
RS (1) RS50853B (sr)
SI (1) SI1776340T1 (sr)
TN (1) TNSN07041A1 (sr)
TW (1) TWI360538B (sr)
UA (1) UA90483C2 (sr)
UY (1) UY29046A1 (sr)
WO (1) WO2006024776A1 (sr)
ZA (1) ZA200700999B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
PE20080145A1 (es) * 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
FR2910473B1 (fr) * 2006-12-26 2009-02-13 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-pyrrolopyridine-2- carboxamides, leur preparation et leur application en therapeutique.
FR2911604B1 (fr) * 2007-01-19 2009-04-17 Sanofi Aventis Sa Derives de n-(heteroaryl-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
WO2009023623A1 (en) * 2007-08-10 2009-02-19 H, Lundbeck A/S Heteroaryl amide analogues
PE20091102A1 (es) 2007-12-17 2009-07-25 Janssen Pharmaceutica Nv Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
FR2926554B1 (fr) * 2008-01-22 2010-03-12 Sanofi Aventis Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926555B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives bicycliques de carboxamides azabicycliques, leur preparation et leur application en therapeutique
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
FR3007850B1 (fr) 2013-06-28 2015-07-17 Probayes Systeme de prediction de temperature

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
KR100508200B1 (ko) * 1996-02-13 2005-12-16 아보트 러보러터리즈 엔도텔린길항제로서의벤조-1,3-디옥솔릴-및벤조푸라닐치환된피롤리딘유도체및이를함유하는약제
TR200501137T2 (tr) * 1997-08-04 2005-12-21 Abbott Laboratories Endotelin antagonistleri.
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EP1463714A4 (en) * 2001-12-10 2005-10-19 Amgen Inc VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
CA2486376A1 (en) * 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
WO2004056768A2 (en) * 2002-12-20 2004-07-08 Bayer Healthcare Ag Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
JP4909068B2 (ja) 2003-02-14 2012-04-04 グラクソ グループ リミテッド カルボキサミド誘導体
US7544803B2 (en) * 2004-01-23 2009-06-09 Amgen Inc. Vanilloid receptor ligands and their use in treatments
FR2874015B1 (fr) * 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AU2005279085B2 (en) 2011-06-16
US7781477B2 (en) 2010-08-24
EA011714B1 (ru) 2009-04-28
AR050283A1 (es) 2006-10-11
JP2008509113A (ja) 2008-03-27
CN101010297B (zh) 2011-07-27
DK1776340T3 (da) 2009-04-06
HRP20090101T3 (en) 2009-03-31
SI1776340T1 (sl) 2009-04-30
KR20070044000A (ko) 2007-04-26
MX2007001436A (es) 2007-04-19
DE602005011450D1 (de) 2009-01-15
US20090286846A1 (en) 2009-11-19
US20080227843A1 (en) 2008-09-18
IL180911A0 (en) 2007-07-04
CA2576727A1 (fr) 2006-03-09
US20070149602A1 (en) 2007-06-28
EA200700400A1 (ru) 2007-06-29
KR101215162B1 (ko) 2012-12-24
PL1776340T3 (pl) 2009-05-29
NZ552924A (en) 2010-08-27
EP1776340B1 (fr) 2008-12-03
ME01663B (me) 2010-08-31
WO2006024776A1 (fr) 2006-03-09
ES2318542T3 (es) 2009-05-01
PE20060557A1 (es) 2006-08-07
PT1776340E (pt) 2009-02-20
UA90483C2 (uk) 2010-05-11
CN101010297A (zh) 2007-08-01
NO20071198L (no) 2007-03-02
FR2874015B1 (fr) 2006-09-15
TNSN07041A1 (fr) 2008-06-02
FR2874015A1 (fr) 2006-02-10
US7582671B2 (en) 2009-09-01
TWI360538B (en) 2012-03-21
ZA200700999B (en) 2008-06-25
US7384969B2 (en) 2008-06-10
UY29046A1 (es) 2006-03-31
CY1108816T1 (el) 2014-04-09
HK1110308A1 (en) 2008-07-11
CR8889A (es) 2007-10-01
EP1776340A1 (fr) 2007-04-25
JP5100381B2 (ja) 2012-12-19
TW200616954A (en) 2006-06-01
MY139286A (en) 2009-09-30
MA28845B1 (fr) 2007-09-03
CA2576727C (fr) 2013-11-26
ECSP077215A (es) 2007-02-28
AU2005279085A1 (en) 2006-03-09
ATE416160T1 (de) 2008-12-15
IL180911A (en) 2011-06-30
BRPI0513087A (pt) 2008-04-22
NO340060B1 (no) 2017-03-06

Similar Documents

Publication Publication Date Title
RS51888B (sr) N-(fenil(piperidin-2-il)metil)benzamidni derivati, njihovo dobijanje i njihova primena u terapiji
RS50853B (sr) Derivati n-(1h-indolil)-1h-indol-2-karboksamida, njihova priprema i njihova primena u terapiji
MEP12608A (en) Derivatives of n-[phenyl (pyrrolidine-2-yl) methyl]benzamide and n-[(azepan-2-yl)phenylmethyl]benzamide, preparation method thereof and application of same in therapeutics
CY1105162T1 (el) Ενωσεις και η χρηση τους ως αναστολεις 5-ητ
PE20070751A1 (es) Derivados de isoxazolidina como inhibidores de la interaccion de proteinas bcl
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MEP12708A (en) Derivatives of n-[phenyl (alkylpiperidine-2-yl) methyl]benzamide, preparation method thereof and application of same in therapeutics
YU39698A (sh) Hinoksalindioni
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
SE0301446D0 (sv) New Compounds
NO20052976L (no) Fosfodiesterase-4-inhibitorer.
RS50980B (sr) Derivati n-hidroksiamida i njihova upotreba
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
HRP20070529T3 (hr) Derivati imidazola kao antagonisti receptora glutamata
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
HRP20050775A2 (en) Quinolinone/benzoxazinone derivatives and uses thereof
RS51358B (sr) Derivati n-(heteroaril)-1h-indol-2-karboksamida i njihova upotreba kao liganda vaniloidnog trpv1 receptora
HUP0303801A2 (hu) Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
NO20073330L (no) Sulfanylsubstituerte fenylmetanoner som glycintransportor 1 (glyt-1) inhibitorer for behandling av nevrologiske og nevropsykiatriske forstyrrelser
HRP20070286T3 (en) Substituted diketopiperazines and their use as oxytocyn antagonists
CY1108837T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΑΜΙΝΟΠΥΡΙΔΙΝΗΣ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ mGluR5